Donate Now
Pages

Author: GhCAdminUsr

Categories
Uncategorized

Managing GERD: Beyond Just Acid Control

Man suffering with severe stomach pain sitting at home. Hand of mature guy holding abdomen suffering from ache, diarrhea or indigestive problem. Caucasian guy pressing on belly on painful sensation

By Dr. Vivek V Gumaste, MD, MRCP(I), MHCM (Harvard)

Gastroesophageal Reflux Disease (GERD) is a common digestive condition that affects about 1 in 4 people in North America. It causes symptoms like heartburn, regurgitation, and chest discomfort. But GERD isn’t just inconvenient, it’s costly and potentially dangerous. Over 4.3 million outpatient visits are made annually for GERD in the U.S., with an average treatment cost of $12,232 per patient. Of this, $4,277 is spent on medications alone.

GERD also increases the risk of developing esophageal cancer. Despite this, many patients don’t respond well to standard treatments like proton pump inhibitors (PPIs). Studies show that up to 50% of people taking PPIs still experience symptoms. Clearly, new solutions are needed

Limitations of Current Testing

Diagnosing GERD can be challenging. Endoscopy often shows normal results, even in symptomatic patients. pH testing, while considered a gold standard, has a high false-negative rate and is uncomfortable. Intraluminal impedance testing adds some value but is still invasive and difficult for patients.

A New Approach: Mucosal Impedance Testing (MIT)

A promising development discussed in wellness forum health communities is Mucosal Impedance Testing (MIT). This method measures the health of the esophageal lining in real time, during an endoscopy. It can identify both acid and non-acid reflux and detect long-term tissue damage. The MiVu device, developed by Diversatek Healthcare, uses a sensor placed on the endoscope to gather data. Studies show MIT may be more accurate than traditional pH tests and is easier on patients.

Could Your Genes Be Behind Your Heartburn?

Genetics also play a big role in GERD. Research shows that 30–40% of GERD risk is inherited. Specific genes, such as FOXF1 and BARX1, have been linked to the disease. These genes may affect how the esophagus develops and functions. There’s also strong genetic overlap between GERD, Barrett’s esophagus, and esophageal cancer, highlighting the need for early detection and tailored treatment.

Precision Medicine and PPIs

PPIs are broken down in the liver by an enzyme called CYP2C19. Depending on a person’s genes, the body may process the drug too quickly or too slowly. Genetic testing (genotyping) can help doctors personalize PPI doses. However, this practice is not yet common in routine care. Summit Healthcare Solutions suggests more clear guidelines are needed before it becomes widespread.

What About Probiotics?

Probiotics are often used for gut health, and some small studies suggest they may help with GERD symptoms like bloating and regurgitation. However, more large-scale, high-quality research is needed to confirm these benefits.

AI and New Drugs

Artificial intelligence (AI) is being used to read diagnostic images, interpret test results, and speed up drug discovery. In Japan, researchers developed a new drug candidate (DQ-18) using AI, showing faster and safer results.

A newly approved drug, Voquezna (vonoprazan), offers quicker relief than PPIs. It works differently and does not need food for activation. Studies show it may be more effective for GERD and peptic ulcers.

The Growing GERD Market

According to Summit Healthcare Solutions, the GERD market in major global regions was worth $5.1 billion in 2024 and could grow to $6.4 billion by 2035. New technology, personalized care, and better drugs are driving this growth.

Final Thoughts

GERD is more than just acid reflux. From genetics and new testing methods to AI and advanced drugs, the future of GERD treatment is rapidly evolving. With better tools and tailored care, millions of patients could finally find lasting relief.

Categories
Cancer Treatment

CAR-T Cell Therapy: A Second Chance at Life—and a Billion-Dollar Biotech Bet

Once a scientific marvel, CAR-T (Chimeric Antigen Receptor T-cell) therapy is now a billion-dollar frontier reshaping cancer care, investment, and innovation.

What is CAR-T Therapy?

CAR-T is a personalized immunotherapy where a patient’s own T cells are extracted, genetically modified to target cancer cells, and then reinfused. This “living drug” teaches the immune system to attack cancer with precision. It’s a multi-step process—leukapheresis, genetic engineering, and re-infusion—followed by monitoring for side effects like cytokine release syndrome (CRS) and neurotoxicity, which are manageable at specialized centers.

Breakthrough Outcomes

CAR-T therapy has delivered unprecedented results, especially in blood cancers like leukemia, lymphoma, and multiple myeloma. Real-world data shows 80–90% response rates, with many patients achieving long-term remission—and even cures. Individuals previously referred for hospice are now walking out cancer-free.

FDA Milestones and Evolving Guidelines

 Since the FDA approved the first CAR-T (Kymriah) in 2017, over six therapies have entered the market, with NCCN and ASCO now recommending CAR-T earlier in treatment for certain cancers. Trials are even testing its use as frontline therapy.

Beyond Blood Cancers

 Though current successes lie in hematologic cancers, efforts are underway to tackle solid tumors (lung, breast, brain, pancreas) using localized delivery and multi-targeted CARs. CAR-T is also being explored for autoimmune diseases like lupus and fibrotic conditions, expanding its future reach far beyond oncology.

Why Investors Are Watching

 The U.S. CAR-T market is expected to grow from $3B in 2023 to over $10B by 2030, with global projections reaching $61B–$129B by 2034. Growth is driven by rising cancer rates, expanding indications, advanced manufacturing, and massive pharma investments. Biotech firms like BMS, Novartis, J&J, and Legend Biotech are all-in.

Tech Meets Medicine

 AI is optimizing CAR-T across the board—from designing safer, more effective CARs to predicting patient response and side effects. Smart manufacturing, including AI-monitored bioreactors and automation, is reducing production time from weeks to days. This convergence of bioengineering and tech is streamlining delivery and expanding access. These advancements were a key focus at the recent Digital Health Innovation Summit, where CAR-T’s future was spotlighted as a leading frontier of tech-driven care.

Policy & Reimbursement

 Medicare covers all FDA-approved CAR-T therapies, reimbursing hospitals significantly. Private insurers also cover CAR-T but require treatment at certified centers. Innovative models like pay-for-response and installment-based reimbursement are being explored. Victim assistance programs are helping bridge access gaps for those facing high out-of-pocket costs.

Market Insights

Final Thought

CAR-T therapy represents a paradigm shift in precision medicine—offering renewed hope for patients once deemed untreatable. For clinicians, it’s a revolutionary tool. For patients, it’s a second chance. For investors and innovators, it’s a rapidly maturing space blending science, technology, and high impact. In many ways, we’re not just treating cancer—we’re rewriting biology’s rulebook.

Categories
Uncategorized

The AI Revolution in Embryo Selection: Transforming Fertility Care Through Data-Driven Precision

By Abhishek Shankar, CEO of MyBabyBridge

The fertility field is undergoing a paradigm shift. Once reliant on microscopes and subjective judgment, embryo selection is now being revolutionized by artificial intelligence (AI). This isn’t just a tech upgrade, it’s a data-driven transformation promising more accurate embryo assessment, higher pregnancy success rates, and broader access to advanced care.

The Limitations of Traditional Embryo Selection

Historically, choosing the right embryo has relied heavily on an embryologist’s trained eye. Yet even experienced professionals agree only about 65% of the time. This inconsistency can lead to different outcomes for similar patients and prolonged treatment cycles—at significant financial and emotional costs, especially given that each IVF round can cost between $15,000 and $25,000.

AI’s Role in Precision Embryology

AI tools, particularly Convolutional Neural Networks (CNNs), analyze subtle patterns in embryo development that humans often miss. Time-lapse imaging further enhances accuracy by tracking embryonic growth over time. Newer approaches integrate imaging, patient history, lab results, and even genetic data, producing robust viability forecasts.

Studies now show AI-assisted embryo selection can predict pregnancy success with up to 82% accuracy, outperforming traditional methods. Some tools also estimate chromosomal normality (euploidy) from visuals alone, potentially reducing the need for invasive genetic testing.

Expanding Access and Standardizing Care

AI is helping decentralize fertility care. Smaller clinics and remote centers can now access high-level embryo evaluation without needing in-house specialists. By using cloud-based AI systems trained on vast datasets, these clinics achieve consistency once limited to large academic institutions.

For clinics, adopting AI improves workflow efficiency, freeing staff for patient care and complex decision-making. Patients benefit from shorter treatment timelines, reduced medication use, and clearer insights into their fertility journey.

Challenges and Regulation

Despite its promise, AI integration comes with challenges. Algorithm transparency and dataset diversity remain critical issues to ensure equitable, explainable results. Gradual implementation, robust staff training, and patient education are essential to preserve trust and uphold ethical standards.

Regulatory bodies like the FDA are now outlining clearer frameworks for AI-based diagnostics, while fertility organizations work to standardize best practices, paving the way for safer, more widespread adoption.

Looking Ahead

Embryo-selection AI is evolving toward real-time, multi-modal systems combining culture monitoring, genomic data, and patient history. Fully automated labs may soon standardize embryo handling and grading, reducing errors and enhancing efficiency.

For patients, this means greater clarity, faster cycles, and improved success rates. For providers, AI offers a competitive edge, provided they invest early in infrastructure, training, and integration.

Conclusion

AI is setting a new standard in fertility care—one that’s more accurate, consistent, and accessible. Clinics embracing this transformation today are not just enhancing outcomes but reshaping the future of reproductive medicine. With thoughtful collaboration among clinicians, engineers, and regulators, AI will continue to elevate care—without losing the human touch at the heart of every family’s journey.

Categories
Revenue Cycle Management (RCM)

Why RCM Outsourcing Is Becoming a Strategic Necessity, Not Just a Cost-Cutting Move

For many years, healthcare organizations viewed Revenue Cycle Management (RCM) outsourcing as a way to cut costs. The main goal was to reduce administrative work and improve profit margins. However, today’s healthcare environment is much more complex. With changing insurance rules, tighter regulations, and higher patient expectations, outsourcing RCM has become a smart and strategic move. In short, outsourcing RCM is no longer optional—it’s essential for long-term sustainability and success.”

What Is RCM?

Revenue Cycle Management (RCM) is how healthcare providers manage the financial side of patient care. It covers tasks like appointment scheduling, insurance checks, managing complex prior authorization, coding, billing, and payment collection. In essence, RCM ensures that providers are reimbursed accurately and in a timely manner

Scalable Growth for Any Practice

Healthcare providers often face changing patient numbers, service needs, and insurance requirements. Whether it is a growing hospital or a small clinic, having the ability to adapt quickly is crucial.

Outsourcing RCM gives providers the flexibility to scale their operations. An RCM partner can handle more or fewer claims as needed without the delays and costs of hiring or training staff.This agility enables providers to expand services, accommodate patient surges, and maintain operational efficiency

Better Compliance with Healthcare Regulations

Healthcare rules are always changing. Keeping up with HIPAA, insurance company rules, and new coding systems like ICD-10 takes time and effort. It can also be risky if mistakes happen.

RCM vendors focus on compliance. They have expert teams and use technology to stay up to date with all the latest rules. Their systems check for errors and make sure claims are correct before submission. This reduces the chance of audits, penalties, and claim rejections.

Faster Payments and Improved Cash Flow

Managing claims is a key part of a healthcare provider’s income. Mistakes in billing or delays in payment can cause cash flow problems.

RCM outsourcing helps speed up the entire billing process. From checking insurance eligibility to submitting claims and handling rejections, everything is done faster and more accurately. This leads to quicker payments and fewer unpaid accounts. As a result, the financial health of the practice improves.

A Better Patient Experience

Patients today expect clear, timely, and professional service—even when it comes to billing. Errors in billing or unclear statements can cause confusion and lower trust in the provider.

With an RCM partner, patients receive accurate bills and helpful support. Many vendors also offer easy payment options and customer service for billing questions. This improves the patient experience and increases satisfaction.

More Time for Patient Care

Outsourcing RCM allows healthcare teams to focus on what matters most: patient care. Instead of spending time on billing and paperwork, providers can concentrate on improving health outcomes and growing their practice.

Conclusion

RCM outsourcing is no longer just about saving money. It is a smart move that helps providers grow, stay compliant, get paid faster, and give better service to patients. In today’s  demanding healthcare environment, the question is no longer whether you can afford to outsource—but whether you can afford not to.

Categories
Hypertension Management

Recent Advances in Hypertension Management: From Precision Medicine to Device-Based Therapies

Executive Summary:

Hypertension (HTN) remains a major global health burden, leading to cardiovascular morbidity and mortality worldwide. While lifestyle modification and pharmacologic therapy remain first-line strategies, a subset of patients continue to exhibit resistant hypertension, prompting exploration of new pharmacological agents and device-based interventions.

Among recent advances, renal denervation (RDN), a minimally invasive procedure, has emerged as a promising therapy for resistant hypertension. RDN involves catheter-based ablation of renal sympathetic nerves to reduce excessive sympathetic activity, a key contributor to high blood pressure (BP).

Recent clinical trials, such as SPYRAL HTN-ON MED, SPYRAL HTN-OFF MED, and RADIANCE-HTN have demonstrated significant BP reductions with RDN. Improved catheter designs and refined procedural techniques enhance precision, minimizing complications.

Beyond RDN, advances in antihypertensive drug development, such as dual endothelin receptor antagonists (e.g., aprocitentan) and aldosterone synthase inhibitors, as well as mineralocorticoid receptor antagonists, are offering new pathways for blood pressure control.

In an era of precision medicine, digital health innovations—such as remote BP monitoring, AI-driven therapeutic guidance, and mobile adherence tools—are augmenting traditional management approaches.

In summary, precision medicine and device-based therapies promise to revolutionize hypertension care, reducing cardiovascular risks and improving patient quality of life.

Hypertension (HTN), commonly known as high blood pressure, remains one of the most pervasive chronic conditions globally. According to the World Health Organization (WHO), approximately 1.28 billion adults aged 30–79 years are affected by hypertension worldwide, with two-thirds living in low- and middle-income countries (WHO, 2021). Despite well-established treatment options involving lifestyle modification and medications, a significant subset of patients have resistant hypertension—failure to achieve adequate blood pressure (BP) control in spite of 3 or more medications.

Recent advances in device-based therapies, novel pharmacological agents, and digital health tools are transforming how clinicians manage hypertension in the era of precision medicine.

What Is Resistant Hypertension?

Resistant hypertension is defined as blood pressure that remains above target despite the concurrent use of three antihypertensive drugs of different classes, one of which is usually a diuretic, at optimal doses. It is estimated that 10–20% of hypertensive individuals may fall into this category.

1. Renal Denervation (RDN): A Game-Changer in Resistant Hypertension

Renal denervation (RDN) is a minimally invasive, catheter-based procedure that reduces renal sympathetic nerve Excessive renal sympathetic drive is a known contributor to hypertension, and RDN addresses this issue directly. Ablation can be done by radiofrequency or ultrasound or drugs..

Key Clinical Trials:
  • SPYRAL HTN-OFF MED Trial: This trial involved patients not on antihypertensive medications. RDN led to a mean reduction of 5.5 mmHg in 24-hour systolic BP compared to the sham group (Townsend et al., 2017).
  • SPYRAL HTN-ON MED Trial: Evaluated RDN in patients already taking medications. Results showed a significant reduction of 9.0 mmHg in office systolic BP (Kandzari et al., 2021).

These trials have reaffirmed RDN as a safe and effective option, especially for patients who are either medication-intolerant or have an inadequate response despite therapy.

2. New kids on the block

Aprocitentan: Dual Endothelin Receptor Antagonist

Aprocitentan works by inhibiting the binding of endothelin-1 (ET-1) to both ETA and ETB receptors, reducing vasoconstriction and sodium retention. In the PRECISION trial, aprocitentan demonstrated sustained BP reduction in resistant hypertension over 48 weeks.

Aldosterone Synthase Inhibitors (ASIs)

ASIs are a class of drugs that target the final enzyme in the process of aldosterone production, called aldosterone synthase (CYP11B2). By inhibiting this enzyme, ASIs reduce circulating aldosterone levels directly. This reduction in aldosterone leads to decreased sodium and water reabsorption, resulting in lower blood volume and blood pressure. 

Next-Generation Mineralocorticoid Receptor Antagonists (MRAs)

Finerenone, a novel mineralocorticoid receptor antagonist (MRA), that selectively blocks MR overactivation in the heart and kidneys. It has a lower risk of hyperkalemia than older drugs like spironolactone and provides cardiorenal protection, particularly in patients with chronic kidney disease and diabetes.

3. Digital Health Innovations in Hypertension Care

Digital tools are redefining hypertension care through remote monitoring, data analytics, and personalized treatment.

Remote BP Monitoring

Wearable and home-based BP monitors now allow patients to track their BP daily and share data with providers in real time, reducing misdiagnosis and white coat HTN.

AI-Based Decision Support

Artificial intelligence is being used to optimize medication regimens, detect trends, and provide alerts for BP fluctuations, increasing care precision.

Conclusion: Toward Precision and Personalization

The management of hypertension is undergoing a paradigm shift with innovations in interventional procedures, drug development, and digital health. The integration of renal denervation, advanced pharmacologic agents, and AI-powered tools offers personalized, effective, and sustainable solutions, particularly for individuals with resistant hypertension.

Ongoing research and long-term follow-ups will be crucial in incorporating these approaches into routine clinical practice and making them accessible across all healthcare settings.

By ACH

Chase
Global Health Forum, Inc.
Account number: 686392278
Routing number (ACH/Wire): 021000021

By Check

RAJEEV KAUL CPA PC
303-5th Avenue, Suite # 1007
New York, NY-10016